Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOLD 100

Next Previous
Drug Profile

BOLD 100

Alternative Names: BOLD 100; IT-139; KP 1339; NKP-1339

Latest Information Update: 25 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical University of Vienna; Queens University Belfast; University of Vienna
  • Developer Bold Therapeutics; Georgetown University; Hana Pharm; Intezyne; University of Ottawa
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors; Molecular chaperone GRP78 protein inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Pancreatic cancer
  • No development reported COVID 2019 infections; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 18 Jun 2025 Bold Therapeutics plans a phase I trial for Soft tissue sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy, First-line therapy) in Canada (IV) in June 2025 (NCT07027423)
  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Oct 2024 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in Canada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top